[ad_1]
Moderna delivered doses of its vaccine candidate, mRNA-1273,351, specific against the SARS-CoV-2 variant first identified in the Republic of South Africa, to the US National Institutes of Health (NIH) for clinical study. . You learn it from the company.
Moderna announced new capital investments to increase the global production capacity of the Covid-19 vaccine: the planned production capacity for 2022 has increased to 1.4 billion doses, and the base plan for 2021 has increased to 700 million doses. And the company is working to supply up to 1 billion doses in 2021. This was announced by the same company, highlighting that the new capital investments “will allow additional production of the current Covid-19 vaccine and guarantee flexibility to cope with production. . of potential booster vaccines against variants “.
Pfizer vaccine is 94% effective against Covid-19. This is established by a study carried out in Israel on 1.2 million people and published today in the prestigious New England Journal of Medicine. “This is the first validated evidence of the effectiveness of a vaccine under real-world conditions,” said Ben Reis, one of the co-authors of the study confirming the crucial role of vaccination campaigns in ending the pandemic.
“To meet the growing demand for vaccine doses, we plan to produce 2 billion doses in 2021, more than 50% of the expected production of 1.3 billion doses. Interventions planned to increase our production capacities are underway. “. ANSA learns from the pharmaceutical company Pfizer explaining: “We are making progress on key initiatives: modification of production processes at the Puurs plant, successfully completed; BioNTech’s production site has received the production license and we will start production for EMA validation in February, according to previously announced plans. “
REPRODUCTION RESERVED © Copyright ANSA
